What research findings exist regarding Liraglutide on weight loss and weight maintenance?
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management. Another study reports: Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[1] ↗ [2] ↗
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2025 · PMID 41160027 | 48 adults with insufficient response after weight loss surgery; 12 months liraglutide randomized controlled trial. | Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management. | Specific postoperative population, small sample, and dropout situation; not general effects in the ordinary population. |
| 2025 · PMID 39401933 | 132 post-gastric bypass weight regain patients; 56-week randomized double-blind trial | Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight. | Completion rate affected by the pandemic; Limited to specific postoperative groups and includes lifestyle counseling. |
| 2025 · PMID 39258838 | 6 to under 12-year-old obese children, randomized trial. | Liraglutide improved BMI-related endpoints compared to placebo. | 2024 online/2025 issue; special conditions for children’s research, not a basis for self-medication. |
| 2015 · PMID 26132939 | 3,731 overweight/obese adults without type 2 diabetes; 56-week SCALE trial | The liraglutide group had an average weight loss of 8.4 kg, compared to 2.8 kg in the placebo group, with more participants reaching the weight loss threshold. | 2015 basic research, both groups received lifestyle interventions; no guarantee of individual effect. |
References
What findings are there in trials of insufficient responders to weight loss surgery?
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management.[1] ↗
48 adults with insufficient response after weight loss surgery; 12 months liraglutide randomized controlled trial.
Specific postoperative population, small sample, and dropout situation; not general effects in the ordinary population.
View the Article Title and Full Citation＋
Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.
JAMA Network Open · Volume/Issue/Year 2025
First published 2025-10-01 · PMID 41160027
DOI 10.1001/jamanetworkopen.2025.39848
What do studies of postoperative weight regain populations show?
Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[2] ↗
132 post-gastric bypass weight regain patients; 56-week randomized double-blind trial
Completion rate affected by the pandemic; Limited to specific postoperative groups and includes lifestyle counseling.
View the Article Title and Full Citation＋
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.
Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery · Volume Issue Year 2025
First published 2024-09-10 · PMID 39401933
DOI 10.1016/j.soard.2024.08.037
Changes in BMI indicators in pediatric obesity randomized trial
Liraglutide improved BMI-related endpoints compared to placebo.[3] ↗
6 to under 12-year-old obese children, randomized trial.
2024 online/2025 issue; special conditions for children’s research, not a basis for self-medication.
View the Article Title and Full Citation＋
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2024-09-10 · PMID 39258838
DOI 10.1056/NEJMoa2407379
What did the SCALE weight management study observe?
The liraglutide group had an average weight loss of 8.4 kg, compared to 2.8 kg in the placebo group, with more participants reaching the weight loss threshold.[4] ↗
3,731 overweight/obese adults without type 2 diabetes; 56-week SCALE trial
2015 basic research, both groups received lifestyle interventions; no guarantee of individual effect.
View the Article Title and Full Citation＋
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
The New England Journal of Medicine · Volume, Issue, Year 2015
First published on 2015-07-02 · PMID 26132939
DOI 10.1056/NEJMoa1411892
Common issues and corresponding evidence
What research findings exist regarding Liraglutide on weight loss and weight maintenance?＋
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management. Another study reports: Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[1] ↗ [2] ↗
Can postoperative weight-loss results of liraglutide be directly extrapolated to the general population?＋
Not allowed. Postoperative weight regain or insufficient initial weight loss applies to specific populations; ordinary overweight/obese adults should refer to corresponding studies such as SCALE, with separate explanations for follow-up and lifestyle interventions.[1] ↗ [2] ↗ [4] ↗
Liraglutide—these conclusions apply to which study populations?＋
48 adults with insufficient response after weight loss surgery; 12 months liraglutide randomized controlled trial; 132 post-Roux-en-Y gastric bypass patients with weight regain; 56-week randomized double-blind trial; 6 to under 12-year-old obese children randomized trial. Specific post-surgery populations, small samples, and dropouts; not generalizable to the overall population.[1] ↗ [2] ↗ [3] ↗
Liraglutide
Return to catalog specifications and batch file verification entry.
